Onconetix (ONCO) Competitors

Onconetix (NASDAQ:ONCO) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.

Does the media prefer ONCO or QTTB?

In the previous week, Q32 Bio had 1 more articles in the media than Onconetix. MarketBeat recorded 4 mentions for Q32 Bio and 3 mentions for Onconetix. Onconetix's average media sentiment score of 0.96 beat Q32 Bio's score of 0.72 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, ONCO or QTTB?

Onconetix has higher revenue and earnings than Q32 Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$1.87M	2.69	-$37.41M	N/A	N/A
Q32 Bio	-$6.65M	-2.86	-$112.96M	-$10.37	-0.15

Is ONCO or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat Q32 Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-2,758.89%	N/A	-48.09%
Q32 Bio	N/A	-146.18%	-54.49%

Which has more risk & volatility, ONCO or QTTB?

Onconetix has a beta of 3.51, meaning that its stock price is 251% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of ONCO or QTTB?

23.9% of Onconetix shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 11.4% of Onconetix shares are held by company insiders. Comparatively, 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor ONCO or QTTB?

Q32 Bio received 12 more outperform votes than Onconetix when rated by MarketBeat users.

Company	Underperform	Outperform
Onconetix	N/A	N/A
Q32 Bio	Outperform Votes 12 63.16%	Underperform Votes 7 36.84%

Do analysts recommend ONCO or QTTB?

Q32 Bio has a consensus price target of $24.71, indicating a potential upside of 1,484.25%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Q32 Bio	0 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Q32 Bio beats Onconetix on 8 of the 15 factors compared between the two stocks.